People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals, Agriculture, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gossamer Bio, Inc. | — | Biotechnology | Series D+ | $632.6M | $3.2B | 2018 |
| Neumora Therapeutics, Inc. | — | Biotechnology | Growth/Late | $474.4M | $19.0B | 2020 |
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Beam Therapeutics Inc. | — | Pharmaceuticals | Series D+ | $218.6M | $4.8B | 2018 |
| AgBiome, LLC | — | Agriculture | Series D+ | $216.7M | $1.2B | 2015 |
| Unity Biotechnology, Inc. | — | Biotechnology | Series D+ | $208.6M | $2.3B | 2013 |
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2015 |
| Autobahn Therapeutics, Inc. | — | Biotechnology | Series D+ | $100.8M | $1.1B | 2024 |
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2015 |
| Sienna Biopharmaceuticals, Inc. | — | Biotechnology | Series C | $58.9M | $1.7B | 2015 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2010 |
| Boragen, Inc. | — | Other | Series B | $43.0M | $32.1M | 2017 |
| Scholar Rock LLC | — | Biotechnology | Series B | $36.3M | $1.4B | 2015 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2012 |
| Kilimanjaro Energy, Inc. | — | Other Technology | Seed | $3.1M | $76.7M | 2010 |
| Trelys, Inc. | — | Biotechnology | Seed | $2.5M | $111.0M | 2013 |
Kristina Burow at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kristina Burow on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 7 | 22 |
| Amir Nashat | 4 | 14 |
| Robert Nelson | 3 | 7 |
| Robert More | 2 | 7 |
| Faheem Hasnain | 2 | 5 |
| Michael Yi | 2 | 4 |
| Nathaniel David | 2 | 3 |
| Steven Gillis | 1 | 23 |
| Richard Lim | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Nina Kjellson | 1 | 11 |
| Chad Waite | 1 | 11 |
| Joel Marcus | 1 | 9 |
| Thomas Erickson | 1 | 7 |
| Steve Dow | 1 | 7 |
| Scott Minick | 1 | 7 |
| William Schleicher | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Michael Gilman | 1 | 6 |
| Vicki Sato | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.